Frühgeborenenretinopathie – Pathophysiologische Grundlagen und aktuelle Behandlungsoptionen

Zusammenfassung

Die Frühgeborenenretinopathie hat ähnlich wie andere neovaskuläre Netzhauterkrankungen in den letzten Jahren den Einzug der Anti-VEGF-Therapie in die klinische Anwendung erlebt. Mit den 2011 publizierten Zwischenergebnissen der BEAT-ROP-Studie wurde erstmals in einer randomisierten und kontrollierten Studie die Wirkung der Anti-VEGF-Therapie mit derjenigen der konventionellen Lasertherapie verglichen. Der vorliegende Übersichtsartikel beleuchtet diese aktuellen Entwicklungen in der Therapie der Frühgeborenenretinopathie aus dem Blickwinkel der pathophysiologischen Grundlagen und leitet daraus ab, in welchen Stadien die Anti-VEGF-Therapie eine begründbare Behandlungsoption darstellt. Darüber hinaus werden den neuen Chancen die noch offenen Fragen einer Anti-VEGF-Therapie bei Frühgeborenenretinopathie gegenübergestellt und aktuelle Studienansätze vorgestellt.

Abstract

Retinopathy of prematurity (ROP), like other angioproliferative retinal disorders, has witnessed the advent of anti-VEGF therapy in clinical practice. The first report from the BEAT-ROP study published in 2011 represents the first comparison of anti-VEGF therapy versus conventional laser treatment in a randomised controlled trial. This review article investigates these novel aspects of ROP therapy from a pathophysiological angle and delineates the stages of ROP in which anti-VEGF treatment appears as a reasonable option. Furthermore, the novel chances of anti-VEGF therapy are being weighed against some still unanswered questions and novel study concepts are being presented.

Schlüsselwörter

Retina - Frühgeborenenretinopathie - ROP

Key words

retina - retinopathy of prematurity - ROP

• Literatur

• 1 Chen J, Stahl A, Hellstrom A et al. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr 2011; 23: 173-178
• 2 Lorenz B. [Current ophthalmic aspects of acute retinopathy of prematurity]. Ophthalmologe 2008; 105: 1092-1100
• 3 Lad EM, Hernandez-Boussard T, Morton JM et al. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009; 148: 451-458
• 4 Dhaliwal CA, Fleck BW, Wright E et al. Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed 2009; 94: F193-195
• 5 Fortes Filho JB, Bonomo PP, Maia M et al. Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies. Graefes Arch Clin Exp Ophthalmol 2009; 247: 831-836
• 6 Perez-Munuzuri A, Fernandez-Lorenzo JR, Couce-Pico ML et al. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr 2010; 99: 519-525
• 7 Wu C, Vanderveen DK, Hellstrom A et al. Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol 2010; 128: 443-447
• 8 Fluckiger S, Bucher HU, Hellstrom A et al. [The early postnatal weight gain as a predictor of retinopathy of prematurity]. Klin Monbl Augenheilkd 2011; 228: 306-310
• 9 Lofqvist C, Andersson E, Sigurdsson J et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124: 1711-1718
• 10 Stahl A, Chen J, Sapieha P et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol 2010; 177: 2715-2723
• 11 Lofqvist C, Hansen-Pupp I, Andersson E et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol 2009; 127: 622-627
• 12 Hard AL, Lofqvist C, Fortes Filho JB et al. Predicting proliferative retinopathy in a Brazilian population of preterm infants with the screening algorithm WINROP. Arch Ophthalmol 2010; 128: 1432-1436
• 13 Wu C, Lofqvist C, Smith LE et al. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol 2012; Epub ahead of print, Apr 9, 2012 (PMID: 22491391)
• 14 Hellstrom A, Perruzzi C, Ju M et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001; 98: 5804-5808
• 15 Sonmez K, Drenser KA, Capone Jr. A et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115: 1065-1070
• 16 Gerhardt H, Golding M, Fruttiger M et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177
• 17 Weidemann A, Krohne TU, Aguilar E et al. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 2010; 58: 1177-1185
• 18 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676
• 19 Pierce EA, Avery RL, Foley ED et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-909
• 20 Sato T, Kusaka S, Shimojo H et al. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009; 116: 1599-1603
• 21 Stahl A, Sapieha P, Connor KM et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res 2010; 107: 495-500
• 22 Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461
• 23 Stahl A, Agostini H, Jandeck C et al. [Pharmacological treatment for retinopathy of prematurity]. Ophthalmologe 2011; 108: 777-787
• 24 Travassos A, Teixeira S, Ferreira P et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007; 38: 233-237
• 25 Wu WC, Yeh PT, Chen SN et al. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011; 118: 176-183
• 26 Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-615
• 27 Sears JE, Pietz J, Sonnie C et al. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology 2009; 116: 513-518
• 28 Askie LM, Henderson-Smart DJ, Ko H. Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants. Cochrane Database Syst Rev 2009; CD001077
• 29 Mantagos IS, Vanderveen DK, Smith LE. Emerging treatments for retinopathy of prematurity. Semin Ophthalmol 2009; 24: 82-86
• 30 Pawlik D, Lauterbach R, Turyk E. Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics 2011; 127: 223-228
• 31 Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity. Neonatology 2011; 100: 116-129
• 32 Bazan NG. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 205-211
• 33 Sapieha P, Stahl A, Chen J et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. Sci Transl Med 2011; 3: 69ra12
• 34 Stahl A, Krohne TU, Sapieha P et al. Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. Br J Ophthalmol 2011; 11: 1496-1501
• 35 Jandeck C, Kellner U, Lorenz B et al. [Guidelines for ophthalmological screening of premature infants in Germany]. Klin Monbl Augenheilkd 2008; 225: 123-130
• 36 Ling CS, Fleck BW Wright Eet al. Diode laser treatment for retinopathy of prematurity: structural and functional outcome. Br J Ophthalmol 1995; 79: 637-641
• 37 Axer-Siegel R, Maharshak I, Snir M et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina 2008; 28: 839-846
• 38 Rudolph G, Buhl M, Pietschmann M et al. [Clinical aspects of retinopathy of prematurity. Results following diode laser coagulation]. Klin Monbl Augenheilkd 2006; 223: 528-533
• 39 Chen J, Connor KM, Aderman CM et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118: 526-533
• 40 Stahl A, Buchwald A, Martin G et al. Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina 2010; 30: 1524-1529
• 41 Joyal JS, Sitaras N, Binet F et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood 2011; 117: 6024-6035
• 42 Redaktionskomitee von DOG BVA und RG. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zum Einsatz von Bevacizumab in der Therapie der Fru¨hgeborenenretinopathie. Ophthalmologe 2012; 109: 197-204
• 43 Hu J, Blair MP, Shapiro MJ et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; Epub ahead of print , Apr 9, 2012 (PMID: 22491394)